New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 25, 2014
10:35 EDTSONC, LEE, AVT, GALT, TCSHigh option volume stocks: LEE TCS AVT SONC GALT
News For LEE;TCS;AVT;SONC;GALT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 27, 2015
14:56 EDTSONCOn The Fly: Weekly technical notes for S&P 500, SanDisk
Subscribe for More Information
March 26, 2015
10:04 EDTTCSOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:00 EDTTCSContainer Store downgraded to Underweight from Hold at BB&T
Subscribe for More Information
March 24, 2015
19:40 EDTSONCOn The Fly: After Hours Movers
Subscribe for More Information
17:41 EDTSONCSonic reports adj. Q2 EPS 13c, consensus 12c
Reports Q2 revenue $126.2M, consensus $123.36M. Reports Q2 system same-store sales increased 11.5%, consisting of an 11.5% same-store sales increase at franchise drive-ins and an increase of 11.2% at company drive-ins.
16:07 EDTSONCSonic sees 25%-27% EPS growth in FY15
Consensus for FY15 EPS is $1.07. The company expects its initiatives to drive 25% to 27% earnings per share growth, on an adjusted basis, in fiscal 2015 as compared to the adjusted non-GAAP earnings per share for fiscal 2014. The macroeconomic environment may impact results.
16:05 EDTSONCSonic sees positive SSS in the low to mid-single digit range for Q3,Q4
Subscribe for More Information
16:03 EDTSONCSonic reports Q2 EPS 14c, consensus 12c
Reports Q2 revenue $126.2M, consensus $123.36M. Reports Q2 system same-store sales increased 11.5%, consisting of an 11.5% same-store sales increase at franchise drive-ins and an increase of 11.2% at company drive-ins.
15:27 EDTSONCNotable companies reporting after market close
Subscribe for More Information
14:03 EDTSONCSonic technical notes before earnings news
Subscribe for More Information
March 23, 2015
10:08 EDTSONCHigh option volume stocks
Subscribe for More Information
07:52 EDTSONCSonic 2015 EPS poised to beat expectations, says Oppenheimer
Subscribe for More Information
March 18, 2015
17:14 EDTGALTGalectin submitted request for SPA with clinical protocol for GR-MD-02 trial
"I am pleased with our many accomplishments during 2014 as we continue to advance programs with GR-MD-02 for the treatment of nonalcoholic steatohepatitis, NASH, with advanced fibrosis. We completed a successful Phase 1 clinical trial and announced final data in January 2015 that were supportive of our plans to begin a Phase 2 program with GR-MD-02 in advanced fatty liver disease, or NASH with fibrosis and cirrhosis," said Peter G. Traber, M.D., president, CEO and chief medical officer of Galectin Therapeutics. "As announced last month, we submitted the Phase 2 clinical trial protocol to the U.S. Food and Drug Administration, FDA, to evaluate the safety and efficacy of GR-MD-02 for the treatment of liver fibrosis and resultant portal hypertension in patients with NASH cirrhosis, the primary endpoint being to determine the change in the hepatic venous pressure gradient, HVPG, as compared with placebo. The FDA has indicated that HVPG may serve as a surrogate primary endpoint for NASH cirrhosis. We submitted a request for a Special Protocol Assessment with the clinical protocol for this trial. Additionally, we are planning to conduct a separate, shorter Phase 2 trial in NASH patients with advanced fibrosis. We expect to begin enrolling patients in both trials during the second quarter of 2015."
17:08 EDTGALTGalectin Therapeutics reports FY14 EPS (78c), consensus (77c)
As of December 31, the company had $29.1M of non-restricted cash and cash equivalents available to fund future operations. In January and February of 2015, the company received $4.1M in net proceeds from the issuance of common shares through its At-the-Market stock issuance program. The company believes that cash on hand of $29.7M as of March 13, is sufficient to fund its operations and research and development activities through September 30, 2016.
09:28 EDTSONCSonic March volatility elevated into Q2 and outlook
Subscribe for More Information
March 16, 2015
17:13 EDTGALTGalectin Therapeutics files form to delay 10-K
Galectin Therapeutics is unable to file, without unreasonable effort or expense, its Annual Report on Form 10-K for the period ended December 31. Because the company was previously a smaller reporting company, this is the first time the company must obtain an audit of its internal control over financial reporting. As a result, additional time is needed for the company to provide its independent auditors with information necessary to complete the audit of the company’s internal control over financial reporting. The company anticipates that its Form 10-K will be filed within the prescribed extension period in accordance with Rule 12b-25(b).

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use